Alimentary Pharmacology & Therapeutics · 2005 · 72 citations · 25 references
MedicineInternal MedicinePharmacologyClinical PharmacologyHepatic PharmacotherapyHepatologyAmino Acid TherapyCirrhosisCirrhosis PharmacotherapyHepatic ImpairmentLiver DiseaseDecompensated Liver Disease ManagementMedical Records Review
BACKGROUND: Patients with decompensated cirrhosis are at risk for hyperfibrinolysis; this is potentially fatal. epsilon-aminocaproic acid has been used to treat patients with hyperfibrinolysis; however, the data about its benefit in the setting of cirrhosis are minimal. AIM: To analyse the efficacy of epsilon-aminocaproic acid and its safety in cirrhotic patients with hyperfibrinolysis. METHODS: All patients with an abnormal euglobin lysis time who were admitted to Rancho Los Amigos Medical Center from 1 January 2001 to 31 December 2002 were included in the study. Their medical records were reviewed and analysed. RESULTS: There were 60 cirrhotic patients with shortened euglobin lysis time. Fifty-two patients received epsilon-aminocaproic acid. Of the 52 patients, seven had one or more bleeding episodes with the subcutaneous or soft tissue bleeding as the most common indication for epsilon-aminocaproic acid use. Of the 37 patients, 34 (92%) had improvement or resolution of their bleeding. Only two (3%) patients had epsilon-aminocaproic acid treatment discontinued because of minor side effects, rash and lightheadedness. There were no thromboembolic complications of treatment. CONCLUSIONS: epsilon-aminocaproic acid was found to be effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis.
25
Epsilon-aminocaproic Acid for Treatment of Fibrinolysis during Liver Transplantation
Yoogoo Kang, Jessica H. Lewis, A. Navalgund et al. · Anesthesiology · 1987 · 227 citations
Medicine, Hematology, Surgery +16
Hemostasis and Fibrinolysis in Severe Liver Failure and Their Relation to Hemorrhage
Anton L. Boks, E.J.P. Brommer, Solko W. Schalm et al. · Hepatology · 1986 · 191 citations · Full text